The COVID-19 pandemic brought shock waves through the world. Strengthening biosafety capabilities has become a highly important issue for all countries in the post-pandemic era. The article summarized a series of initiatives that the United States (US), the United Kingdom(UK) and the European Union(EU) have launched intensively during the pandemic, involving strategic actions, institutional reforms, capacity building, etc. In general, the US, UK and EU have increased strategic investment in biosafety, seeking technological changes to maintain situational awareness of biological threats, and strengthen medical defense capabilities, such as diagnostics, vaccines and therapeutics. Notably, the US, UK, and EU have established permanent pandemic coordination and response agencies. In addition, the US, UK and the EU have been trying to release innovative incentives for the markets to deal with the serious risks caused by insufficient R&D pipelines against antimicrobial resistance, beyond increasing the R&D investments. These policies and initiatives of the US, UK and EU are instructive for China, and we need to establish a more comprehensive biosafety strategy with active investment to be prepared for future risks.